|
|
Volumn 25, Issue 2, 2011, Pages 135-138
|
|
Trials define anti-tumor effects of anti-resorptive agents: Denosumab ahead of zoledronate 2 to 1
a,b
|
|
Author keywords
Antineoplastics, therapeutic use; Cancer, treatment; Denosumab, therapeutic use; Osteoclast inhibitors, therapeutic use; Research and development; Zoledronic acid, therapeutic use
|
|
Indexed keywords
ALENDRONIC ACID;
ANASTROZOLE;
DENOSUMAB;
RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;
RECLAS;
TAMOXIFEN;
UNCLASSIFIED DRUG;
ZOLEDRONIC ACID;
ANTINEOPLASTIC ACTIVITY;
ARTICLE;
BONE MASS;
BONE METASTASIS;
BREAST CANCER;
CANCER GROWTH;
CANCER SURVIVAL;
DRUG EFFECT;
DRUG EFFICACY;
DRUG SAFETY;
HUMAN;
JAW OSTEONECROSIS;
MULTIPLE MYELOMA;
OSTEOPOROSIS;
OVERALL SURVIVAL;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
PROSTATE CANCER;
QUALITY OF LIFE;
T LYMPHOCYTE;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
BONE DENSITY CONSERVATION AGENTS;
CLINICAL TRIALS AS TOPIC;
DIPHOSPHONATES;
HUMANS;
IMIDAZOLES;
NEOPLASMS;
RANK LIGAND;
|
|
EID: 79953179033
PISSN: 11738804
EISSN: 1179190X
Source Type: Journal
DOI: 10.2165/11590730-000000000-00000 Document Type: Article |
|
Times cited : (4)
|
|
References (4)
|
